- Home
- WHF vs CRBP Comparison
WHF vs CRBP Comparison
Compare WHF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- CRBP
- Stock Information
- Founded
- WHF 2011
- CRBP 2009
- Country
- WHF United States
- CRBP United States
- Employees
- WHF N/A
- CRBP N/A
- Industry
- WHF Finance Companies
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- CRBP Health Care
- Exchange
- WHF Nasdaq
- CRBP Nasdaq
- Market Cap
- WHF 243.6M
- CRBP 227.3M
- IPO Year
- WHF 2012
- CRBP N/A
- Fundamental
- Price
- WHF $10.54
- CRBP $17.47
- Analyst Decision
- WHF Hold
- CRBP Strong Buy
- Analyst Count
- WHF 4
- CRBP 7
- Target Price
- WHF $12.25
- CRBP $65.86
- AVG Volume (30 Days)
- WHF 93.4K
- CRBP 334.8K
- Earning Date
- WHF 11-07-2024
- CRBP 11-07-2024
- Dividend Yield
- WHF 14.61%
- CRBP N/A
- EPS Growth
- WHF N/A
- CRBP N/A
- EPS
- WHF 0.45
- CRBP N/A
- Revenue
- WHF $97,441,000.00
- CRBP N/A
- Revenue This Year
- WHF N/A
- CRBP N/A
- Revenue Next Year
- WHF N/A
- CRBP N/A
- P/E Ratio
- WHF $23.61
- CRBP N/A
- Revenue Growth
- WHF N/A
- CRBP N/A
- 52 Week Low
- WHF $10.42
- CRBP $4.00
- 52 Week High
- WHF $13.44
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- WHF 28.82
- CRBP 42.37
- Support Level
- WHF $10.42
- CRBP $15.65
- Resistance Level
- WHF $11.79
- CRBP $17.18
- Average True Range (ATR)
- WHF 0.21
- CRBP 1.18
- MACD
- WHF -0.05
- CRBP 0.38
- Stochastic Oscillator
- WHF 8.76
- CRBP 35.55
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.